Within the C-144–01 study, which evaluates the efficacy and safety of Lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma previously treated with anti-LAG3 antibody a small proportion of patients who failed prior therapy with nivolumab plus relatlimab achieved durable responses with an ORR of 38.5% [60]. This evidence concerns the gene LAG3 and neoplasm.